[JPM 2025] Korea's next-gen leaders eye global biopharma future

SAN FRANCISCO -- Heirs to Korea’s leading conglomerates stepped onto the global biopharma stage at this year’s JP Morgan Healthcare Conference, highlighting their ambitions in the pharmaceutical and biotech sectors. At the conference held Monday through Thursday in San Francisco, key figures including Seo Jin-seok of Celltrion, Shin Yoo-yeol of Lotte Biologics, and Chey Yoon-chung of SK Biopharmaceuticals, underscored their companies’ commitment to future growth by building connections with part

Jan. 17, 2025

[JPM 2025] Lotte Biologics to provide one-stop ADC services at Syracuse Campus

SAN FRANCISCO ― Lotte Biologics CEO James Park unveiled the firm’s new platform for antibody-drug conjugates, a promising class of anticancer drugs, as its biopharmaceutical production facility in the US is getting ready to welcome its first client. At the JP Morgan Healthcare Conference's Asia-Pacific sessions on Thursday, the pharmaceutical unit of Lotte Group introduced its proprietary and innovative ADC platform, SoluFlex Link, and announced plans to provide one-stop ADC services in collabor

Jan. 17, 2025

Samsung Biologics powers up ADC business with new facility, key partnerships

SAN FRANCISCO -- Samsung Biologics has made a major move into the antibody-drug conjugate market, announcing that its newly constructed 500-liter ADC-dedicated production facility will commence operations this February. Joseph Jeong, vice president of the ADC Development Team at Samsung Biologics, highlighted the rationale behind the expansion, emphasizing the company’s ability to leverage its established expertise in monoclonal antibody CDMO services to advance ADC therapeutics. "Samsung Biolog

Jan. 16, 2025

Hanmi Pharmaceutical steps up in global obesity drug race

SAN FRANCISCO ― Hanmi Pharmaceutical is poised to bring a new chapter to obesity treatment, a topic that has garnered significant attention at this year’s JP Morgan Healthcare Conference. Despite the spotlight on obesity drugs, industry concerns remain about potential side effects such as nausea, vomiting and overall muscle loss, which could lead to further complications for patients. Choi In-young, senior vice president and head of Hanmi Pharmaceutical's R&D Center, expressed confidence in the

Jan. 16, 2025

[JPM 2025] Celltrion highlights breakthrough therapies, unveils ambitious clinical plans by 2028

SAN FRANCISCO -- Celltrion unveiled a detailed road map for its innovative drug pipeline to global investors and expressed commitment to becoming a leading global player in innovative pharmaceuticals, expanding forward from a biosimilar-focused company. At the JP Morgan Healthcare Conference's main stage venue Tuesday, Celltrion CEO Seo Jin-seok delivered a presentation titled "Unveiling Strategy for Advancing Innovative Drug Pipelines," sharing its achievements in drug development and plans for

Jan. 15, 2025

[JPM 2025] Samsung Biologics broadens biopharma horizons with new drug modalities

Samsung Group's biotech arm aims for major capacity boost, adding 720,000 liters through its second bio campus by 2032 SAN FRANCISCO-- Samsung Biologics CEO John Rim unveiled the company's strategy to ascend as a top-tier biopharmaceutical company, grounded in its "4E (Excellence)" approach, unveiled at the JP Morgan Healthcare Conference held in San Francisco, on Tuesday. The 4E framework encompasses the values that Samsung Biologics' employees embody: customer excellence, operational excellenc

Jan. 15, 2025

SK Biopharm, Eurofarma form JV to launch AI epilepsy platform in North America

SAN FRANCISCO -- SK Biopharmaceuticals plans to establish a joint venture with Eurofarma, one of Latin America’s leading pharmaceutical companies, to commercialize a new AI-based epilepsy management platform in North America. “We first connected with Eurofarma at the AES (American Epilepsy Society) three years ago, and this partnership has come to represent a new chapter in SK Biopharm's global expansion,” said SK Biopharmaceuticals CEO Lee Dong-hoon during a press briefing held in San Francisco

Jan. 15, 2025

[Herald Interview] Pakistan's population boom beckons Korean businesses: commerce minister

Highlighting Pakistan’s increasing demand for South Korea’s advanced technologies and expertise, Federal Commerce Minister Jam Kamal Khan emphasized vast opportunities for collaboration, supported by Pakistan’s young, tech-savvy workforce. Following the signing of the Economic Partnership Agreement between the two countries with Trade Minister Cheong In-kyo on Thursday, Khan addressed shared challenges, noting that many of Pakistani companies would benefit from trade agreements with Korea that r

Jan. 14, 2025

Samsung Biologics secures largest-ever deal with European pharma giant

Samsung Group biotech unit is now Kospi's fourth-biggest company, outpacing world's largest CDMO, Lonza, in market cap Samsung Biologics has kicked off the start of 2025 with the largest single contract in the company's history, signing a record-breaking $1.41 billion deal, amounting to some 40 percent of the total orders received last year. On Tuesday, the company disclosed that it had signed a large-scale contract manufacturing organization agreement with a European pharmaceutical company. The

Jan. 14, 2025

[Photo News] Kolon takes the wheel in Vietnam

Korean chemical and textile manufacturing company Kolon Industries announced Tuesday its plans to invest 30 billion won ($20.5 million) in expanding the company's tire cord production in Vietnam. The investment will boost production capacity to 57,000 metric tons annually by 2027, with the company repurposing idle equipment from its shuttered Nanjing plant in China to cut costs. The initiative supports Kolon's strategy to strengthen its global tire cord market presence and address increasing dem

Jan. 14, 2025